Advances in Stroke Prevention

Plenary Symposium at the 11th European Stroke Conference
Geneva, Switzerland, May 29–June 1, 2002
Supported by an Educational Grant from Sanofi-Synthelabo

Editors
Julien Bogousslavsky, Lausanne
Marie-Germaine Bousser, Paris

13 figures and 6 tables, 2003
Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Contents

1 Introduction
Bousser, M.-G. (Paris); Bogousslavsky, J. (Lausanne)

3 Long-Term Outcome after Stroke due to Atrial Fibrillation
Mattle, H.P. (Bern)

9 Outcome after Brain Haemorrhage
Dennis, M.S. (Edinburgh)

14 Long-Term Outcome after Ischaemic Stroke/Transient Ischaemic Attack
Hankey, G.J. (Perth)

20 Evidence with Antiplatelet Therapy and ADP-Receptor Antagonists
Easton, J.D. (Providence, R.I.)